Precigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit

Rhea-AI Summary

Precigen, Inc. (Nasdaq: PGEN) announced that Dr. Helen Sabzevari, President and CEO, will join a virtual panel on June 30, 2022, at 1:00 PM ET during the Stifel 2022 Virtual Cell Therapy Summit. The discussion will focus on Targeted T Cell Therapies, including CAR T and TCR therapies. Precigen specializes in gene and cell therapies aimed at treating urgent diseases in immuno-oncology, autoimmune disorders, and infectious diseases. More details about the event can be found on Precigen's website.

GERMANTOWN, Md., June 27, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual panel discussion titled, "Targeted T Cell Therapies, Including Autologous CAR T, TCR and More" on Thursday, June 30, 2022, at 1:00 PM ET at the Stifel 2022 Virtual Cell Therapy Summit.

Event details can be found on Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.

Precigen: Advancing Medicine with Precision^™

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen, LinkedIn or YouTube.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

Investor Contact: 
Steven M. Harasym 
Vice President, Investor Relations 
Tel: +1 (301) 556-9850 
investors@precigen.com

Media Contacts: 
Donelle M. Gregory 
press@precigen.com

Glenn Silver 
Lazar-FINN Partners 
glenn.silver@finnpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-participate-in-the-stifel-2022-virtual-cell-therapy-summit-301576136.html

SOURCE Precigen, Inc.

FAQ

What event is Precigen participating in on June 30, 2022?

Precigen is participating in the Stifel 2022 Virtual Cell Therapy Summit.

Who represents Precigen in the virtual panel discussion?

Dr. Helen Sabzevari, President and CEO of Precigen, will represent the company.

What topics will be discussed at the Stifel 2022 Virtual Cell Therapy Summit?

The panel will focus on Targeted T Cell Therapies, including CAR T and TCR therapies.

Where can I find more information about the Stifel 2022 Virtual Cell Therapy Summit?

More information can be found on Precigen's Events & Presentations section of their website.

What is the stock symbol for Precigen?

The stock symbol for Precigen is PGEN.